Elbasvir/Grazoprevir (Zepatier) for Hepatitis C
February 29, 2016 (Issue: 1489)
The FDA has approved Zepatier (Merck), a fixed-dose
combination of two direct-acting antiviral
agents — elbasvir, an NS5A inhibitor, and grazoprevir,
an NS3/4A protease inhibitor — for oral treatment
of chronic hepatitis C virus (HCV)...more
- JP Messina et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61:77.
- A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C. Med Lett Drugs Ther 2014; 56:111.
- In brief: new indications for Harvoni. Med Lett Drugs Ther 2016; 58:6.
- A 4-drug combination (Viekira Pak) for hepatitis C. Med Lett Drugs Ther 2015; 57:15.
- In brief: Technivie for HCV genotype 4 infection. Med Lett Drugs Ther 2015; 57: e162.
- American Association for the Study of Liver Diseases/Infectious Disease Society of America/International Antiviral Society– USA. Recommendations for testing, managing, and treating hepatitis C. December 11, 2015. Available at www. hcvguidelines.org. Accessed February 18, 2016.
- S Zeuzem et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163:1.
- JK Rockstroh et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2:e319.
- P Kwo et al. Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 or 16 weeks in patients with HCV G1, G4 or G6 infection who previously failed peginterferon/RBV : C-EDGE treatment-experienced. EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver; Vienna, Austria; April 22-26. Available at www.natap. org. Accessed February 18, 2016.
- X Forns et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015; 63:564.
- M Buti et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis 2016; 62:32.
- D Roth et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 386:1537.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
